Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study

Maximilian J. Hochmair, Alessandro Morabito, Desiree Hao, Cheng Ta Yang, Ross A. Soo, James C.H. Yang, Rasim A. Gucalp, Balazs Halmos, Lara Wang, Angela Märten, Tanja Cufer

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077.

Original languageEnglish (US)
Pages (from-to)2905-2914
Number of pages10
JournalFuture Oncology
Volume15
Issue number25
DOIs
StatePublished - Jan 1 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Observational Studies
Treatment Failure
Mutation
Survival
Survival Analysis
osimertinib
BIBW 2992
Neoplasms

Keywords

  • afatinib
  • NSCLC
  • osimertinib
  • sequential
  • T790M

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : Updated analysis of the observational GioTag study. / Hochmair, Maximilian J.; Morabito, Alessandro; Hao, Desiree; Yang, Cheng Ta; Soo, Ross A.; Yang, James C.H.; Gucalp, Rasim A.; Halmos, Balazs; Wang, Lara; Märten, Angela; Cufer, Tanja.

In: Future Oncology, Vol. 15, No. 25, 01.01.2019, p. 2905-2914.

Research output: Contribution to journalReview article

Hochmair, Maximilian J. ; Morabito, Alessandro ; Hao, Desiree ; Yang, Cheng Ta ; Soo, Ross A. ; Yang, James C.H. ; Gucalp, Rasim A. ; Halmos, Balazs ; Wang, Lara ; Märten, Angela ; Cufer, Tanja. / Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : Updated analysis of the observational GioTag study. In: Future Oncology. 2019 ; Vol. 15, No. 25. pp. 2905-2914.
@article{365ebed5c7174b918cbc095811edb8b0,
title = "Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study",
abstract = "Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90{\%} CI: 36.8-46.3) overall and 45.7 months (90{\%} CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82{\%}, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90{\%} CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077.",
keywords = "afatinib, NSCLC, osimertinib, sequential, T790M",
author = "Hochmair, {Maximilian J.} and Alessandro Morabito and Desiree Hao and Yang, {Cheng Ta} and Soo, {Ross A.} and Yang, {James C.H.} and Gucalp, {Rasim A.} and Balazs Halmos and Lara Wang and Angela M{\"a}rten and Tanja Cufer",
year = "2019",
month = "1",
day = "1",
doi = "10.2217/fon-2019-0346",
language = "English (US)",
volume = "15",
pages = "2905--2914",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "25",

}

TY - JOUR

T1 - Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer

T2 - Updated analysis of the observational GioTag study

AU - Hochmair, Maximilian J.

AU - Morabito, Alessandro

AU - Hao, Desiree

AU - Yang, Cheng Ta

AU - Soo, Ross A.

AU - Yang, James C.H.

AU - Gucalp, Rasim A.

AU - Halmos, Balazs

AU - Wang, Lara

AU - Märten, Angela

AU - Cufer, Tanja

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077.

AB - Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077.

KW - afatinib

KW - NSCLC

KW - osimertinib

KW - sequential

KW - T790M

UR - http://www.scopus.com/inward/record.url?scp=85071633846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071633846&partnerID=8YFLogxK

U2 - 10.2217/fon-2019-0346

DO - 10.2217/fon-2019-0346

M3 - Review article

C2 - 31370698

AN - SCOPUS:85071633846

VL - 15

SP - 2905

EP - 2914

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 25

ER -